BACKGROUND:Health status is a key outcome for comparing treatments, particularly when mortality does not differ significantly. METHODS AND RESULTS:Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) randomized 2368 patients with type 2 diabetes mellitus and stable ischemic heart disease to (1) prompt revascularization versus medical therapy and (2) insulin sensitization versus insulin provision. Randomization was stratified by the intended method of revascularization, coronary artery bypass graft surgery or percutaneous coronary intervention. The Duke Activity Status Index and RAND Energy, Health Distress, and Self-Rated Health scales were assessed at study entry and annually thereafter; linear mixed models were used to evaluate the effect of randomized treatment on these measures. Health status improved significantly from baseline to 1 year (P<0.001) in each randomized treatment group. Compared with medical therapy, prompt revascularization was associated with significantly greater improvements in Duke Activity Status Index (1.32 points; P<0.001), Energy (1.36 points; P=0.02), and Self-rated Health (1.77 points; P=0.007) but not Health Distress (-0.47; P=0.46). These treatment effects were largely maintained over 4 years of follow-up. The effect of revascularization on the Duke Activity Status Index was significantly larger in the subgroup of patients intended for coronary artery bypass graft surgery compared with the subgroup intended for percutaneous coronary intervention. Health status did not differ significantly on any of the 4 measures between the insulin provision and insulin sensitization strategies. CONCLUSIONS: Prompt coronary revascularization was associated with small yet statistically significant improvements in health status compared with initial medical therapy among patients with diabetes mellitus and stable ischemic heart disease. CLINICAL TRIAL REGISTRATION: http://www.clinicaltrials.gov. Unique identifier: NCT00006305.
RCT Entities:
BACKGROUND: Health status is a key outcome for comparing treatments, particularly when mortality does not differ significantly. METHODS AND RESULTS: Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) randomized 2368 patients with type 2 diabetes mellitus and stable ischemic heart disease to (1) prompt revascularization versus medical therapy and (2) insulin sensitization versus insulin provision. Randomization was stratified by the intended method of revascularization, coronary artery bypass graft surgery or percutaneous coronary intervention. The Duke Activity Status Index and RAND Energy, Health Distress, and Self-Rated Health scales were assessed at study entry and annually thereafter; linear mixed models were used to evaluate the effect of randomized treatment on these measures. Health status improved significantly from baseline to 1 year (P<0.001) in each randomized treatment group. Compared with medical therapy, prompt revascularization was associated with significantly greater improvements in Duke Activity Status Index (1.32 points; P<0.001), Energy (1.36 points; P=0.02), and Self-rated Health (1.77 points; P=0.007) but not Health Distress (-0.47; P=0.46). These treatment effects were largely maintained over 4 years of follow-up. The effect of revascularization on the Duke Activity Status Index was significantly larger in the subgroup of patients intended for coronary artery bypass graft surgery compared with the subgroup intended for percutaneous coronary intervention. Health status did not differ significantly on any of the 4 measures between the insulin provision and insulin sensitization strategies. CONCLUSIONS: Prompt coronary revascularization was associated with small yet statistically significant improvements in health status compared with initial medical therapy among patients with diabetes mellitus and stable ischemic heart disease. CLINICAL TRIAL REGISTRATION: http://www.clinicaltrials.gov. Unique identifier: NCT00006305.
Authors: Maria Mori Brooks; Robert L Frye; Saul Genuth; Katherine M Detre; Richard Nesto; Burton E Sobel; Sheryl F Kelsey; Trevor J Orchard Journal: Am J Cardiol Date: 2006-04-17 Impact factor: 2.778
Authors: M A Hlatky; R E Boineau; M B Higginbotham; K L Lee; D B Mark; R M Califf; F R Cobb; D B Pryor Journal: Am J Cardiol Date: 1989-09-15 Impact factor: 2.778
Authors: Joseph Kim; Robert A Henderson; Stuart J Pocock; Tim Clayton; Mark J Sculpher; Keith A A Fox Journal: J Am Coll Cardiol Date: 2005-01-18 Impact factor: 24.094
Authors: M A Hlatky; W J Rogers; I Johnstone; D Boothroyd; M M Brooks; B Pitt; G Reeder; T Ryan; H Smith; P Whitlow; R Wiens; D B Mark Journal: N Engl J Med Date: 1997-01-09 Impact factor: 91.245
Authors: K R Lorig; D S Sobel; A L Stewart; B W Brown; A Bandura; P Ritter; V M Gonzalez; D D Laurent; H R Holman Journal: Med Care Date: 1999-01 Impact factor: 2.983
Authors: W Ken Redekop; Marc A Koopmanschap; Ronald P Stolk; Guy E H M Rutten; Bruce H R Wolffenbuttel; Louis W Niessen Journal: Diabetes Care Date: 2002-03 Impact factor: 19.112
Authors: Sheng-Chia Chung; Mark A Hlatky; David Faxon; Kodangudi Ramanathan; Dale Adler; Arshag Mooradian; Charanjit Rihal; Roslyn A Stone; Joyce T Bromberger; Sheryl F Kelsey; Maria Mori Brooks Journal: J Am Coll Cardiol Date: 2011-08-16 Impact factor: 24.094
Authors: Mouin S Abdallah; Kaijun Wang; Elizabeth A Magnuson; John A Spertus; Michael E Farkouh; Valentin Fuster; David J Cohen Journal: JAMA Date: 2013-10-16 Impact factor: 56.272
Authors: Ronald J Krone; Andrew D Althouse; Jacqueline Tamis-Holland; Lakshmi Venkitachalam; Arturo Campos; Alan Forker; Alice K Jacobs; Salvador Ocampo; George Steiner; Francisco Fuentes; Ivan R Pena Sing; Maria Mori Brooks Journal: Can J Cardiol Date: 2014-08-20 Impact factor: 5.223
Authors: Gregg W Stone; Judith S Hochman; David O Williams; William E Boden; T Bruce Ferguson; Robert A Harrington; David J Maron Journal: J Am Coll Cardiol Date: 2015-11-23 Impact factor: 24.094
Authors: Megan Coylewright; Kathy Shepel; Annie Leblanc; Laurie Pencille; Erik Hess; Nilay Shah; Victor M Montori; Henry H Ting Journal: PLoS One Date: 2012-11-30 Impact factor: 3.240